ライフサイエンスコーパス: canagliflozin

1 nts (35%) sitagliptin and 175 patients (38%) canagliflozin.

2 nation, may modify the treatment benefits of canagliflozin.

3 ibuting to the beneficial cardiac effects of canagliflozin.

4 pagliflozin, and 3.58 (CI, 2.13 to 6.03) for canagliflozin.

5 aglutide and in 20 (5%) of 394 patients with canagliflozin.

6 ned largely unchanged in those randomized to canagliflozin.

7 the majority of amputations were observed on canagliflozin.

8 lozin, with 5% for empagliflozin, and 1% for canagliflozin.

9 ted by the synthesis of the SGLT2 inhibitor, canagliflozin.

10 lied to the synthesis of the alpha-anomer of canagliflozin.

11 umin-to-creatinine ratio decreased more with canagliflozin 100 mg (31.7%; 95% CI, 8.6% to 48.9%; P=0.

12 ed at least one dose of glimepiride (n=482), canagliflozin 100 mg (n=483), or canagliflozin 300 mg (n

13 In the canagliflozin 100 mg and 300 mg groups versus the glimep

14 the glimepiride group versus 24 (5%) in the canagliflozin 100 mg group and 26 (5%) in the 300 mg gro

15 with each of sitagliptin 100 mg once daily, canagliflozin 100 mg once daily and pioglitazone 30 mg o

16 tive voice or web response system to receive canagliflozin 100 mg or 300 mg, or glimepiride (up-titra

17 For lowering of HbA1c at 52 weeks, canagliflozin 100 mg was non-inferior to glimepiride (le

18 (pioglitazone 30 mg, sitagliptin 100 mg and canagliflozin 100 mg).

19 Glimepiride, canagliflozin 100 mg, and canagliflozin 300 mg groups ha

20 n and randomly assigned to either once-daily canagliflozin 100 mg, canagliflozin 300 mg, or glimepiri

21 Patients receiving glimepiride, canagliflozin 100 mg, or canagliflozin 300 mg had reduct

22 r 1 year of treatment with either placebo or canagliflozin 100 mg/day, in approximately 2,600 individ

23 In 666 T2DM patients randomized to receive canagliflozin 100 or 300 mg or placebo, the study assess

24 In conclusion, canagliflozin 100 or 300 mg/d, compared with glimepiride

25 rsal, or ankle fracture was also similar for canagliflozin (14.5 events per 1000 person-years) and GL

26 ted by the synthesis of the SGLT2 inhibitor, canagliflozin (1a), from commercially available 10 in on

27 rate of the primary outcome was similar for canagliflozin (2.2 events per 1000 person-years) and GLP

28 $1.30 to $3.45 per month for SGLT2Is (except canagliflozin: $25.00-$46.79) and from $0.75 to $72.49 p

29 gned to semaglutide 1.0 mg (394 patients) or canagliflozin 300 mg (394 patients).

30 mg (31.7%; 95% CI, 8.6% to 48.9%; P=0.01) or canagliflozin 300 mg (49.3%; 95% CI, 31.9% to 62.2%; P<0

31 de (n=482), canagliflozin 100 mg (n=483), or canagliflozin 300 mg (n=485).

32 Glimepiride, canagliflozin 100 mg, and canagliflozin 300 mg groups had eGFR declines of 3.3 ml/

33 eiving glimepiride, canagliflozin 100 mg, or canagliflozin 300 mg had reductions in HbA1c of 0.81%, 0

34 kly semaglutide 1.0 mg was superior to daily canagliflozin 300 mg in reducing HbA(1c) and bodyweight

35 neous semaglutide 1.0 mg once weekly or oral canagliflozin 300 mg once daily.

36 fference -0.01% [95% CI -0.11 to 0.09]), and canagliflozin 300 mg was superior to glimepiride (-0.12%

37 d to either once-daily canagliflozin 100 mg, canagliflozin 300 mg, or glimepiride uptitrated to 6-8 m

38 Significantly more participants in the canagliflozin (45%) compared to the placebo (21%) group

39 HbA1c on pioglitazone 59.5 sitagliptin 59.9, canagliflozin 60.5 mmol mol(-1), P = 0.19).

40 59.6 mmol/mol, sitagliptin 60.0 mmol/mol and canagliflozin 60.6 mmol/mol (P = 0.2).

41 Oral administration of canagliflozin activated AMPK in mouse liver, although no

42 A single dose of canagliflozin administered shortly into ischemic insult

43 We investigated the potential of acute canagliflozin administration to mitigate acute kidney in

44 This study suggests that canagliflozin, aliskiren, and darunavir may induce profo

45 We now report that canagliflozin also activates AMPK, an effect also seen w

46 Although canagliflozin also inhibited cellular glucose uptake ind

47 Canagliflozin also inhibited lipid synthesis, an effect

48 semaglutide (a GLP-1 receptor agonist) with canagliflozin (an SGLT2 inhibitor) in patients with type

49 nergy calculations and inhibition assays for canagliflozin, an antidiabetic agent verified its effect

50 lbuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100

51 We explored the direct effects of canagliflozin, an SGLT2 inhibitor with mild SGLT1 inhibi

52 We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in p

53 curred infrequently (4% of participants with canagliflozin and 2% with placebo).

54 subgroups of age, sex, and frailty; and for canagliflozin and dapagliflozin individually.

55 At baseline, the mean serum potassium in canagliflozin and placebo arms was 4.5 mmol/L; 4395 (99.

56 Serum sST2 was unchanged with canagliflozin and placebo over 104 weeks.

57 ence in median percent change between pooled canagliflozin and placebo were -15.0%, -16.1%, and -26.8

58 Assessment Study) Program and the CREDENCE (Canagliflozin and Renal Events in Diabetes with Establis

59 in approximately 2,600 individuals from the Canagliflozin and Renal Events in Diabetes with Establis

60 We conducted a joint analysis of canagliflozin and renal events in diabetes with establis

61 zin Cardiovascular Assessment] and CREDENCE [Canagliflozin and Renal Events in Diabetes with Establis

62 agliflozin were established by the CREDENCE (Canagliflozin and Renal Events in Diabetes With Establis

63 ologue of the extensively characterized drug canagliflozin and thus shares its toxicological and phar

64 s for these transporters (eg, dapagliflozin, canagliflozin, and empagliflozin) can slow the rate of i

65 pecific inhibitors, including dapagliflozin, canagliflozin, and empagliflozin, increase glucose excre

66 Empagliflozin, dapagliflozin, and canagliflozin are all potent and selective inhibitors of

67 including empagliflozin, dapagliflozin, and canagliflozin, are now widely approved antihyperglycemic

68 Patients in the canagliflozin arm and in the top quartile of urine gluco

69 These findings support the use of canagliflozin as a viable treatment option for patients

70 l examination of kidney sections reveal that canagliflozin attenuates ISO-mediated increases in infla

71 senger RNA expression data demonstrated that canagliflozin augments antioxidant and anti-inflammatory

72 ypertension and diabetes, aliskiren-based or canagliflozin-based drug design against HIV-1 PR may eli

73 weeks with placebo and remained stable with canagliflozin (between-group difference +7.3% (2.0-12.8)

74 Autoradiography showed [(18)F]canagliflozin binding in human kidney sections containin

75 Here, we investigated if canagliflozin can reverse isoprenaline (ISO)-induced ren

76 e studied the impact of 1, 3, or 6 months of canagliflozin (CANA), an SGLT2i treatment, on the skelet

77 -glucose cotransporter 2 inhibitor (SGLT2i), canagliflozin (Cana; 30 mg/kg/day), could restore exerci

78 nhibitors: empagliflozin (EMPA-REG OUTCOME), canagliflozin (CANVAS Program and CREDENCE), and dapagli

79 atinine ratio (uEGF/Cr) was measured in 3521 CANagliflozin cardioVascular Assessment Study (CANVAS) p

80 nducted a post-hoc analysis of data from the CANagliflozin cardioVascular Assessment Study (CANVAS) P

81 In the CANVAS (CANagliflozin cardioVascular Assessment Study) biomarker

82 d high CV risk or nephropathy in the CANVAS (CANagliflozin cardioVascular Assessment Study) Program a

83 The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) randomly

84 The CANVAS trial (Canagliflozin Cardiovascular Assessment Study) subsequen

85 We used data from 2 SGLT2i trials (CANVAS [Canagliflozin Cardiovascular Assessment] and CREDENCE [C

86 odds ratio for a drop in eGFR over 10% with canagliflozin compared to placebo was significant at 3.0

87 hort, the primary end point was reduced with canagliflozin compared with placebo (26.9 versus 31.5/10

88 AMPK activation occurred at canagliflozin concentrations measured in human plasma in

89 y weight, BP, and albuminuria, implying that canagliflozin confers renoprotection.

90 Canagliflozin consistently reduced CV death or HHF in pa

91 Canagliflozin, dapagliflozin, and empagliflozin accounte

92 Canagliflozin, dapagliflozin, and empagliflozin, all rec

93 s individual agents in the SGLT-2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) and GLP-1 r

94 summarise data from eight clinical trials of canagliflozin, dapagliflozin, empagliflozin, and sotagli

95 SONAR trials, which assessed the effects of canagliflozin, dapagliflozin, finerenone and atrasentan

96 ntrolled trials that assessed the effects of canagliflozin, dapagliflozin, finerenone, atrasentan, lo

97 First dispensing of canagliflozin, dapagliflozin, or empagliflozin without a

98 We determined whether canagliflozin decreases albuminuria and reduces renal fu

99 dium-glucose cotransporter 2 inhibition with canagliflozin decreases HbA1c, body weight, BP, and albu

100 Compared with placebo, treatment with canagliflozin delayed the rise in serum NT-proBNP and hs

101 Canagliflozin delays longitudinal rise in hs-cTnT and sS

102 und of the 95% CI for the difference of each canagliflozin dose versus glimepiride of less than 0.0%.

103 ty margin of 0.3% for the comparison of each canagliflozin dose with glimepiride.

104 , urinary tract infections (31 [6%] for both canagliflozin doses vs 22 [5%]), and osmotic diuresis-re

105 Canagliflozin effects on CV death or HHF were assessed b

106 Patients on SGLT2i, including canagliflozin, empagliflozin, dapagliflozin, and ertugli

107 of LLA was similar in patients treated with canagliflozin, empagliflozin, or dapagliflozin.

108 he previously reported risks associated with canagliflozin except for an increased risk of amputation

109 Because of the disproportionate canagliflozin exposure in the database, the majority of

110 visits, to test the efficacy of 12 weeks of canagliflozin for the treatment of heart failure, regard

111 The canagliflozin group also had a lower risk of cardiovascu

112 e and cardiovascular events was lower in the canagliflozin group than in the placebo group at a media

113 of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with even

114 , 0.4 to 1.4), respectively (P<0.01 for each canagliflozin group versus glimepiride).

115 (367 in the semaglutide group and 372 in the canagliflozin group).

116 ardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events

117 Compared to controls, animals receiving canagliflozin had less severe AKI, improved creatinine c

118 Canagliflozin had striking ex vivo transcriptomic effect

119 orter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular mo

120 HbA(1c) and bodyweight than those receiving canagliflozin (HbA(1c) estimated treatment difference [E

121 or canagliflozin-renin; K(i,exp)= 628 nM for canagliflozin-HIV-1 PR).

122 iflozin (HR 0.814, 95% CI 0.774, 0.855), and canagliflozin (HR 0.893, 95% CI 0.862, 0.926).

123 For MI/stroke risk, both canagliflozin (HR, 0.98; 95% CI, 0.91-1.05) and dapaglif

124 CHIEF-HF (Canagliflozin: Impact on Health Status, Quality of Life

125 ed risk of amputation has been observed with canagliflozin in 1 previous trial.

126 efore, we investigated protective effects of canagliflozin in ISO-induced cardiac oxidative stress, a

127 dies have investigated protective effects of canagliflozin in isoprenaline (ISO)-induced cardiac oxid

128 ggest a potential novel therapeutic role for canagliflozin in mitigating the effects of renal IRI wor

129 provide further insights into the effects of canagliflozin in these patient populations.

130 he sodium-glucose cotransporter 2 (SGLT2) by canagliflozin in type 2 diabetes mellitus results in lar

131 ct infections, occurred more frequently with canagliflozin, in 136 (35%) of 394 patients.

132 Subcutaneous semaglutide and canagliflozin increased diabetic retinopathy and amputat

133 Canagliflozin increased kidney tissue expression of EGF

134 ts with type 2 diabetes and CKD treated with canagliflozin, individuals with the highest glycosuria l

135 safety events, compared with empagliflozin, canagliflozin initiators had a lower risk of genital inf

136 We show that one such compound, canagliflozin (Invokana), a type-2 diabetes drug already

137 Canagliflozin is a sodium glucose cotransporter 2 inhibi

138 Background Canagliflozin is a sodium-glucose cotransporter 2 inhibi

139 Canagliflozin is associated with decreased bone mineral

140 The antidiabetic drug canagliflozin is reported to possess several cardioprote

141 Since [(18)F]canagliflozin is the isotopologue of the extensively cha

142 Canagliflozin lowered albuminuria with greater proportio

143 years in patients with type 2 diabetes, and canagliflozin may confer renoprotective effects independ

144 one system inhibitors, SGLT2 inhibition with canagliflozin may reduce the risk of hyperkalaemia in pe

145 19, 4.61) lower HbA1c on sitagliptin than on canagliflozin (n = 342, P = 0.001).

146 to-treat approach, we assessed the effect of canagliflozin on a composite outcome of time to either i

147 of this study was to examine the effects of canagliflozin on cardiovascular biomarkers in older pati

148 We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outco

149 m of this study was to assess the effects of canagliflozin on CV outcomes according to baseline estim

150 molecular mechanisms of the SGLT2 inhibitor canagliflozin on EGF using single-cell RNA sequencing fr

151 ; n=324), and CHIEF-HF (A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Fun

152 ong-term trajectory of each, and response to canagliflozin on key cardiovascular and kidney outcomes.

153 used ex vivo to study the direct effects of canagliflozin on NADPH oxidase activity and nitric oxide

154 The proportional effects of canagliflozin on renal and cardiovascular outcomes are m

155 e dedicated renal protection trial CREDENCE (Canagliflozin on Renal and Cardiovascular Outcomes in Pa

156 We assessed effects of canagliflozin on renal, cardiovascular, and safety outco

157 th empagliflozin initiators, those receiving canagliflozin or dapagliflozin were less likely to have

158 action and randomized 1:1 to 100 mg daily of canagliflozin or matching placebo.

159 nts with T2DM and CKD to the SGLT2 inhibitor canagliflozin or matching placebo.

160 each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of

161 iabetes status, were randomized to 100 mg of canagliflozin or placebo.

162 ts with T2DM and high cardiovascular risk to canagliflozin or placebo.

163 articipants with type 2 diabetes mellitus to canagliflozin or placebo.

164 A single 300 mg dose of oral canagliflozin or vehicle (saline) was delivered 5 mins i

165 Further, canagliflozin prevents ISO-induced apoptosis of kidney c

166 In summary, we demonstrated that canagliflozin produces cardioprotective actions by promo

167 Canagliflozin provides greater HbA1c reduction than does

168 Canagliflozin reduced cardiovascular and renal outcomes

169 Canagliflozin reduced CV and kidney events in patients w

170 Canagliflozin reduced heart failure and kidney events re

171 Canagliflozin reduced NADPH oxidase activity via AMP kin

172 oteins (DeltaG(pred) = -9.1 kcal mol(-1) for canagliflozin-renin; K(i,exp)= 628 nM for canagliflozin-

173 ith and without diabetes, demonstrating that canagliflozin significantly improves symptom burden in H

174 Canagliflozin significantly reduced CV death or HHF comp

175 Canagliflozin significantly slowed increases of hs-cTnT

176 Canagliflozin similarly reduced the incidence of laborat

177 After week 13, canagliflozin slowed the annual loss of kidney function

178 Canagliflozin slows the progression of chronic kidney di

179 Our results also show that canagliflozin stimulates antioxidant/anti-inflammatory s

180 We demonstrate for the first time that canagliflozin suppresses myocardial NADPH oxidase activi

181 e assembly products, we show that YX-I-1 and canagliflozin target IAPP early in aggregation, remodeli

182 e rate of the primary outcome was lower with canagliflozin than with placebo (occurring in 26.9 vs. 3

183 ce interval, 0.8-7.8; P = 0.016) higher with canagliflozin than with placebo, meeting the primary end

184 itiation of potassium binders was lower with canagliflozin than with placebo.

185 of all participants following initiation of canagliflozin, the clinical benefit of canagliflozin was

186 ta suggest a potential additional benefit of canagliflozin therapy compared with other SGLT2 inhibito

187 ized clinical trial for a new indication for canagliflozin to improve the symptoms of patients with h

188 ave greater relative reductions in MACE from canagliflozin treatment (P(interaction trend) = 0.005).

189 In addition, canagliflozin treatment attenuates pro-oxidative, pro-in

190 The Sglt2 inhibitor canagliflozin treatment had no effect on Agt and Sglt2 e

191 Consistently, canagliflozin treatment improves heart function marker i

192 Finally, consistent with these findings, canagliflozin treatment improves kidney function in ISO-

193 In contrast, canagliflozin treatment in ISO rats not only preserves e

194 Canagliflozin treatment increased fractional urinary glu

195 Strikingly, canagliflozin treatment of ISO-treated rats not only pre

196 Long-term canagliflozin use attenuates renal function decline and

197 ctin-3 modestly increased from baseline with canagliflozin versus placebo, with significant differenc

198 tron emission tomography (PET) tracer [(18)F]canagliflozin was developed via a Cu-mediated (18)F-fluo

199 2 diabetes and relatively low fracture risk, canagliflozin was not associated with increased risk for

200 on of canagliflozin, the clinical benefit of canagliflozin was observed regardless.

201 Because an increased risk of amputation with canagliflozin was reported in the CANVAS trials, there h

202 The mean serum potassium over time with canagliflozin was similar to that of placebo.

203 nts with CKD, the kidney and CVD benefits of canagliflozin were established by the CREDENCE (Canaglif

204 79 964 patients initiating use of canagliflozin were identified and matched to 79 964 pati

205 ns with type 2 diabetes who initiated use of canagliflozin were propensity score-matched in a 1:1 rat

206 idney safety profiles, in those treated with canagliflozin were similar across eGFR decline categorie

207 he GMP automated synthesis originated [(18)F]canagliflozin with a yield of 0.5-3% (n = 4) and a purit

208 nt, the results showed a possible benefit of canagliflozin with respect to the progression of albumin

209 ll patients the overall most preferred drug (canagliflozin), would result in more patients achieving